Table II.
Comparison of relative quantitative expression values of CD44v6, MMP-2 and survivin mRNAs among the experimental groups (n=8).
| Variable | Survivin mRNA | CD44v6 mRNA | MMP-2 mRNA |
|---|---|---|---|
| Control | 1.073 ± 0.078 | 1.026 ± 0.037 | 1.008 ± 0.017 |
| Oxaliplatin | 0.617 ± 0.017a,b | 0.697 ± 0.011a,b | 0.771 ± 0.012a,b |
| Indomethacin | 0.616 ± 0.018a,b | 0.707 ± 0.010a,b | 0.783 ± 0.011a,b |
| Combination | 0.426 ± 0.024a | 0.469 ± 0.012a | 0.520 ± 0.011a |
| P-value | <0.01 | <0.01 | <0.01 |
a
P<0.05 vs. control group
b
P<0.05 vs. indomethacin combined with oxaliplatin-treated group. CD44v6, cluster of differentiation 44 variant 6; MMP-2, matrix metalloproteinase-2; SD, standard deviation; mRNA, messenger RNA. Data presented as the mean ± standard deviation.